Caixin Securities released a research report on April 8 stating that Gloria Ying (002821.SZ) was given a buying rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) the regular business grew rapidly after excluding large orders, and foreign customers and major pharmaceutical companies contributed major increases; 3) the clinical phase III project of small molecule CDMO services covered multiple major drug targets such as GLP-1, with sufficient commercial order reserves; 4) the company strives to increase non-COVID-19 business revenue by 15.00% to 25.00% in 2024. (Mainichi Keizai Shimbun)
财信证券4月8日发布研报称，给予凯莱英（002821.SZ）买入评级。评级理由主要包括：1）事件：公司发布2023年年度报告；2）剔除大订单后的常规业务增长迅速，国外客户、大制药公司贡献主要增量；3）小分子CDMO服务的临床III期项目涵盖GLP-1等多个大药靶点，商业化订单储备充足；4）公司力争2024年非新冠业务收入增长15.00%-25.00%。（每日经济新闻）
Caixin Securities released a research report on April 8 stating that Gloria Ying (002821.SZ) was given a buying rating. The main reasons for the rating include: 1) incident: the company released its 2023 annual report; 2) the regular business grew rapidly
The translation is provided by third-party software.
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.